Ocugen (NASDAQ:OCGN) Receives Buy Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Ocugen (NASDAQ:OCGN) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock.

A number of other research firms have also recently issued reports on OCGN. Canaccord Genuity Group assumed coverage on Ocugen in a report on Tuesday, March 17th. They issued a “buy” rating and a $12.00 price objective for the company. Wall Street Zen upgraded Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. HC Wainwright increased their price target on shares of Ocugen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Oppenheimer started coverage on shares of Ocugen in a research note on Wednesday, March 11th. They set an “outperform” rating and a $10.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.75.

Ocugen Price Performance

Shares of NASDAQ:OCGN opened at $1.95 on Wednesday. The company’s fifty day moving average price is $1.73 and its 200-day moving average price is $1.53. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market capitalization of $639.41 million, a price-to-earnings ratio of -8.48 and a beta of 2.75. Ocugen has a one year low of $0.57 and a one year high of $2.73.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The company had revenue of ($0.19) million during the quarter, compared to analyst estimates of $0.86 million. On average, equities research analysts anticipate that Ocugen will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ocugen

A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its holdings in Ocugen by 56.7% in the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after buying an additional 13,326 shares during the period. SmartHarvest Portfolios LLC purchased a new position in shares of Ocugen during the 4th quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd raised its position in shares of Ocugen by 76,831.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 82,317 shares of the company’s stock worth $111,000 after acquiring an additional 82,210 shares in the last quarter. UBS Group AG raised its position in shares of Ocugen by 373.2% in the 4th quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock worth $6,547,000 after acquiring an additional 3,824,474 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Ocugen in the 4th quarter valued at approximately $289,000. 10.27% of the stock is owned by institutional investors.

Trending Headlines about Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Topline Phase 2 ArMaDa data: the optimal OCU410 dose showed a 31% reduction in GA lesion growth at 12 months, structural preservation signals, no OCU410-related serious adverse events, and a plan to start Phase 3 in Q3 2026 — a clear clinical milestone that supports a sizeable long-term value case. Ocugen Announces Topline 12-month Data (GlobeNewswire)
• Positive Sentiment: Analyst support: HC Wainwright raised its price target to $10 (Buy) and Chardan reaffirmed a Buy with a $7 target — both indicate sizable upside expectations based on the Phase 2 readout and anticipated Phase 3. Benzinga analyst coverage
• Positive Sentiment: Balance-sheet commentary: recent coverage highlights Ocugen’s healthy cash position and manageable operating spend, which reduces near-term financing risk as the company advances OCU410 toward Phase 3. OCGN Has A Healthy Cash Position (Yahoo Finance)
• Neutral Sentiment: Company call/transcript and analyses are available for deeper read-throughs of subgroup data and safety details; these will matter to investors assessing Phase 3 design and market potential. Phase II transcript (Seeking Alpha)
• Neutral Sentiment: Third-party summaries (Quiver/others) reiterate the 31% result and highlight potential advantages vs. current therapies, but note forward-looking uncertainty — helpful context but not fresh catalysts. QuiverQuant summary
• Neutral Sentiment: Short-interest reports in recent feeds showed anomalous/zero values and NaN changes — data appears unreliable; treat reported short-interest moves with caution until exchanges publish confirmed figures.
• Negative Sentiment: Market reaction and critical headlines: some outlets framed the Phase 2 results as “lagging” earlier expectations (reporting the outcome as smaller than prior hints), which prompted selling pressure and short-term underperformance. Ocugen Falls — Yahoo
• Negative Sentiment: Additional negative headlines and analyst caution: Zacks and MarketWatch/other outlets highlighted the stock drop and framed the release as a mixed outcome — media focus on the “tanks/falls” narrative amplified volatility despite the statistically significant primary endpoint. Ocugen Falls — Zacks

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.